Can Gönen

Guselkumab in Patients With Moderately to Severely Active Ulcerative Colitis: QUASAR Phase 2b Induction Study

Laurent Peyrin‐Biroulet, Jessica R. Allegretti, David T. Rubin et al. · Gastroenterology · 2023 · 86 citations · Full text

Efficacy and safety of mirikizumab in patients with moderately-to-severely active Crohn's disease: a phase 3, multicentre, randomised, double-blind, placebo-controlled and active-controlled, treat-through study

Marc Ferrante, Geert D’Haens, Vipul Jairath et al. · The Lancet · 2024 · 76 citations

Moderately-to-severely Active Crohn, Immunology, Gastroenterology +5

Comparison of High Resolution Magnifying Endoscopy and Standard Videoendoscopy for the Diagnosis of <i>Helicobacter pylori</i> Gastritis in Routine Clinical Practice: A Prospective Study

Can Gönen, İlkay Şımşek, Sülen Sarıoğlu et al. · Helicobacter · 2009 · 65 citations

Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies

David T. Rubin, Jessica R. Allegretti, Julián Panés et al. · The Lancet · 2024 · 62 citations · Full text

Placebo-controlled Induction, Gastroenterology, Pathology +6

Development of an E-learning System for the Endoscopic Diagnosis of Early Gastric Cancer: An International Multicenter Randomized Controlled Trial

Kenshi Yao, Noriya Uedo, Manabu Muto et al. · EBioMedicine · 2016 · 55 citations · Full text